Search a ticker

Categories
Featured Health Care Stocks Investing Stock Market Today Stocks to Watch

Top Stocks To Invest In Right Now? 5 Health Care Stocks To Watch

Check out these health care firms taking center stage in the stock market now.

stocks to invest in right now

Are These The Best Health Care Stocks To Invest In Right Now?

As investors consider the current state of the stock market now, health care stocks could become increasingly viable plays. Overall, this would be understandable seeing as markets are having a mostly rocky start to 2022. Between surging inflation, increasing coronavirus infections and a less-than-ideal start to the earnings season from banks, investors could be turning to more vital industries. In turn, this could be where health care stocks come into play.

If anything, there is no shortage of exciting news to consider in the health care world now. On one hand, you have upcoming names in the biotech space making groundbreaking discoveries and strategic plays. Take Mainz Biomed (NASDAQ: MYNZ) for instance. Since acquiring the exclusive rights to Novel mRNA biomarkers via a deal with Socpra Sciences, MYNZ stock has doubled in value. In theory, the deal allows Mainz Biomed to employ these biomarkers in the development of ColoAlert. This would be its at-home screening test candidate for colorectal cancer.

At the same time, pharmaceutical giants such as Pfizer (NYSE: PFE) continue to press forward as well. On the heels of its life-saving work on the coronavirus vaccine, Pfizer is now looking towards universal flu vaccines. Just last week, Pfizer’s VP of Viral Vaccine Research  highlight that mRNA vaccines could help in the development of “higher potency flu vaccines.” Nevertheless, the health care industry remains as busy as ever now. Could one of these health care stocks be your next big investment?

Top Health Care Stocks To Buy [Or Sell] Right Now

Theseus Pharmaceuticals 

Theseus Pharmaceuticals is a biotech company that strives to improve the lives of cancer patients. It is led by a team of targeted oncology pioneers with a proven track record for developing and commercializing cancer therapeutics. Its lead program, THE-630 is a pan-variant KIT inhibitor for patients with advanced gastrointestinal stromal tumors (GIST). THRX stock enjoyed gains of over 20% on Friday.

This seems to follow news that it announced in the earlier part of last week. Diving in, it announced that the first patient has been treated in the Phase 1 portion of Theseus’ ongoing Phase 1/2 trial to evaluate its THE-630 candidate in GIST patients.

“Patients with unresectable or metastatic GIST who have exhausted standard therapies have limited treatment options and poor clinical outcomes. GIST disease progression remains largely KIT-dependent even after multiple lines of therapy, and a significant unmet need remains for these patients,” said Suzanne George, M.D., Clinical Director, Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute. Given this piece of news, is THRX stock worth paying attention to this week?

[Read More] Best Lithium Battery Stocks To Buy Now? 4 To Know

Prometheus Biosciences

Prometheus Biosciences is a biotech company that pioneers precision medicine for the discovery and development of novel therapeutics and companion diagnostic product candidates. The company focuses on both gastrointestinal and autoimmune diseases. Through its power precision medicine platform, Prometheus360, it combines proprietary technology with the world’s most comprehensive collection of inflammatory bowel disease (IBD) patient data. RXDX stock is up by over 39% in the past year alone.

Last week, the company provided a corporate update at the 40th Annual J.P. Morgan Healthcare Conference. In it, the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Prometheus’ lead therapeutic candidate, PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD).

Based on its positive topline Phase 1 results and this Fast Track Designation, the company believes that PRA023 is well-positioned to deliver and have a broad impact on patients with SSc-ILD. If it were to prove successful in its Phase 2 clinical trials, Prometheus would seek Breakthrough Therapy Designation in SSc-ILD given that there are no approved disease-modifying therapies in the market today. For this reason, is RXDX stock a health care stock to invest in right now?

UnitedHealth Group

UnitedHealth Group is a multinational health care and insurance company. The company is dedicated to helping people live healthier lives and making health care work for everyone. It offers a full spectrum of health benefit programs for individuals, employers, and Medicare and Medicaid beneficiaries.

It also contracts directly with more than 1.3 million physicians and care professionals. Furthermore, UnitedHealth provides health benefits and delivers care to people through its health care facilities in South America.

On January 12, 2022, the company’s Optum subsidiary launched a new evidence engine to advance genomics-based disease detection and treatment. The Optum Evidence Engine will accelerate the generation of clinical validity and utility evidence for molecular diagnostics. It also helps standardize evidence requirements and speeds the adoption of precision medicine. With that being said, is UNH stock a top health care stock in your books?

[Read More] Best Monthly Dividend Stocks To Buy Now? 5 For Your List

Moderna 

Following that, we have Moderna, a pharmaceutical and biotechnology company that focuses on RNA therapeutics, primarily through its messenger RNA (mRNA) vaccines. The company has a broad intellectual portfolio in mRNA and lipid nanoparticle formulation.

It also has an integrated manufacturing plant that facilitates both clinical and commercial production at scale and at an unprecedented speed. MRNA stock is up by over 60% in the past year.

For one thing, the company continues to press forward on the operational front. Notably, CEO Stephane Bancel recently provided an update on Moderna’s work with the Omicron coronavirus variant. Bancel notes that Moderna’s answer to the prominent variant is “being finished,” with clinical data incoming. To be precise he notes that data could arrive by March 2022. After considering all this, would you consider MRNA stock a buy at its current value?

[Read More] Best Artificial Intelligence Stocks To Buy Right Now? 5 To Watch

Allogene Therapeutics 

Another name to consider among health care firms now would be Allogene Therapeutics. In brief, it is a clinical-stage biotech firm that focuses on researching treatments for cancer. Not to mention, the company is a pioneering player in the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products. According to Allogene, the company is hard at work on its pipeline of off-the-shelf CAR T cell product candidates. The likes of which will, ideally, serve as an on-demand cell therapy to patients at a larger scale.

Notably, ALLO stock ended last week with gains of over 8%. Accordingly, this could be on account of its latest collaboration. As of last week, the company is currently working with Antion Biosciences, a Swiss biotech firm. Through the current agreement, Allogene currently has a global license to use Antion’s miRNA tech (miCAR). In doing so, Allogene is looking to advance its work on a multiplex gene silencing tool.

Subsequently, this will be crucial in developing next-gen allogeneic CAR T offerings. According to Allogene CMO Dr. Rafael Amado, miCAR can deliver a “high degree of specificity and potency,” on this front. Because of all this, will you be adding ALLO stock to your watchlist?

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!

By Adam Lawrence

Adam Lawrence is a serial entrepreneur and financial writer for StockMarket.com. He calls Miami, Florida his home but has a love for travel. He started his first digital marketing and website design business, in 2006 at the age of 23. He has worked with and consulted for hundreds of publicly traded companies. His vast knowledge of the public markets has allowed him to gain real-world experience in corporate communications. No matter what is going on in the stock market today, Adam is at the front of the line to track new trends and present them to readers.

As an active contributor to other financial sites like GuruFocus and Benzinga, Adam has gained prominence for reporting on several topics. These include biotech stocks, technology stocks, gold stocks, as well as marijuana stocks. These active stock market sectors have presented investors with some of the biggest opportunities in the stock market today. Adam's goal is to present readers with easily digestible content that is both informative and actionable.

Adam's years of experience in digital marketing have helped give him an edge above other financial writers. His ability to pick up on stock market trends before they hit Main Street is one of the things that has afforded him the opportunity to interact with and engage public companies. Reporting on current events is one thing but being able to dissect them and translate them for readers is of the utmost importance. In doing so, Adam has set a personal standard to deliver timely information that dives deeper than simple headlines and goes into the fine details of what's driving stock market trends. He also stays on top of the most current social media trends among top influencers.

With the emerging landscape surrounding new media, Adam takes an active approach to learn what drives interest in different social media and finds ways to tap into whatever is trending at that time then apply it to his approach to the stock market. In his free time, he enjoys being with his family and working on his house. He's also an avid car enthusiast.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments